Evidence map›Paper›PMID 24799836›Full record

ArticleGastroenterology & hepatology2014

Patterns of acetaminophen use exceeding 4 grams daily in a hospitalized population at a tertiary care center.

Jesse M Civan, Victor Navarro, Steven K Herrine, Jeffrey M Riggio, Paul Adams, Simona Rossi

Open access · greenAbstract read
In one paragraph

Article in Gastroenterology & hepatology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
2.9field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. NCPDP recommendations for dose accumulation monitoring in the inpatient setting: Acetaminophen case model, version 1.0.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · 2016
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Jesse M CivanDr Civan is the director of the Liver Tumor Program, Dr Herrine is a professor in the Division of Gastroenterology & Hepatology, Dr Riggio is an associate professor in the Division of Hospital Medicine, and Dr Adams is a clinical informatics pharmacist in the Department of Pharmacy at Thomas Jefferson University Hospital in Philadelphia, Pennsylvania. Dr Navarro is a professor of medicine, pharmacology, and experimental therapeutics and the medical director of the Hepatology and the Liver Transplant Program at the Einstein Medical Center in Philadelphia, Pennsylvania, where Dr Rossi is the associate chair of the Division of Hepatology.
Victor NavarroDr Civan is the director of the Liver Tumor Program, Dr Herrine is a professor in the Division of Gastroenterology & Hepatology, Dr Riggio is an associate professor in the Division of Hospital Medicine, and Dr Adams is a clinical informatics pharmacist in the Department of Pharmacy at Thomas Jefferson University Hospital in Philadelphia, Pennsylvania. Dr Navarro is a professor of medicine, pharmacology, and experimental therapeutics and the medical director of the Hepatology and the Liver Transplant Program at the Einstein Medical Center in Philadelphia, Pennsylvania, where Dr Rossi is the associate chair of the Division of Hepatology.
Steven K HerrineDr Civan is the director of the Liver Tumor Program, Dr Herrine is a professor in the Division of Gastroenterology & Hepatology, Dr Riggio is an associate professor in the Division of Hospital Medicine, and Dr Adams is a clinical informatics pharmacist in the Department of Pharmacy at Thomas Jefferson University Hospital in Philadelphia, Pennsylvania. Dr Navarro is a professor of medicine, pharmacology, and experimental therapeutics and the medical director of the Hepatology and the Liver Transplant Program at the Einstein Medical Center in Philadelphia, Pennsylvania, where Dr Rossi is the associate chair of the Division of Hepatology.
Jeffrey M RiggioDr Civan is the director of the Liver Tumor Program, Dr Herrine is a professor in the Division of Gastroenterology & Hepatology, Dr Riggio is an associate professor in the Division of Hospital Medicine, and Dr Adams is a clinical informatics pharmacist in the Department of Pharmacy at Thomas Jefferson University Hospital in Philadelphia, Pennsylvania. Dr Navarro is a professor of medicine, pharmacology, and experimental therapeutics and the medical director of the Hepatology and the Liver Transplant Program at the Einstein Medical Center in Philadelphia, Pennsylvania, where Dr Rossi is the associate chair of the Division of Hepatology.
Paul AdamsDr Civan is the director of the Liver Tumor Program, Dr Herrine is a professor in the Division of Gastroenterology & Hepatology, Dr Riggio is an associate professor in the Division of Hospital Medicine, and Dr Adams is a clinical informatics pharmacist in the Department of Pharmacy at Thomas Jefferson University Hospital in Philadelphia, Pennsylvania. Dr Navarro is a professor of medicine, pharmacology, and experimental therapeutics and the medical director of the Hepatology and the Liver Transplant Program at the Einstein Medical Center in Philadelphia, Pennsylvania, where Dr Rossi is the associate chair of the Division of Hepatology.
Simona RossiDr Civan is the director of the Liver Tumor Program, Dr Herrine is a professor in the Division of Gastroenterology & Hepatology, Dr Riggio is an associate professor in the Division of Hospital Medicine, and Dr Adams is a clinical informatics pharmacist in the Department of Pharmacy at Thomas Jefferson University Hospital in Philadelphia, Pennsylvania. Dr Navarro is a professor of medicine, pharmacology, and experimental therapeutics and the medical director of the Hepatology and the Liver Transplant Program at the Einstein Medical Center in Philadelphia, Pennsylvania, where Dr Rossi is the associate chair of the Division of Hepatology.
Hospital of the University of Pennsylvania · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Unintentional acetaminophen-induced hepatotoxicity has been increasingly recognized as a significant problem, prompting increased scrutiny and restrictions from the US Food and Drug Administration on products combining acetaminophen with narcotics. Patterns of acetaminophen use have not previously been reported in the hospitalized patient population, which may be especially vulnerable to liver injury. We aimed to quantify the frequency at which acetaminophen dosing exceeded the recommended maximum of 4 g/day in hospitalized patients. This was a retrospective, single-center, cohort study at a large tertiary care academic hospital. We queried our inpatient electronic medical record database to identify patients admitted between 2008 and 2010 who were receiving cumulative daily acetaminophen doses exceeding 4 g on at least 1 hospital day. Of 43,761 admissions involving acetaminophen administration, the recommended maximum cumulative daily dose of 4 g was exceeded in 1119 (2.6%) cases. Patients who were administered a larger number of acetaminophen-containing medications were more likely to receive doses in excess of the recommended maximum. Alanine aminotransferase (ALT) levels were checked within 14 days following acetaminophen exposure in excess of 4 g in 35 (3.1%) cases. Excessive acetaminophen dosing of hospitalized patients, who may be at increased risk for acetaminophen-induced hepatotoxicity, occurred in a minority of patients. The use of multiple acetaminophen-containing medication formulations contributed to excessive dosing. ALT level monitoring in this group was infrequent, precluding assessment of biochemical evidence of liver injury. This cohort of patients may represent an ideal population for further prospective study with more intensive and longer-term biochemical monitoring to assess for evidence of liver injury.

Indexed as

Acetaminophendrug-induced liver injurydrug safetyhepatotoxicityhospitalized patients

Identifiers

PMID24799836
PMCPMC4008956
OpenAlexW2184216512

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.